MedTrace Logo

Regulatory Post-Marketing Surveillance Study for Brolucizumab

NCT04985487 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-01-14

No results posted yet for this study

Summary

This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

OTHER

brolucizumab

Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2026-06-14
Completion
2026-06-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04985487 on ClinicalTrials.gov